Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. 2004

Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
Department of Anatomy and Neuroscience, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.

Recent studies have suggested that neuronal death in Alzheimer's disease or ischemia could arise from dysfunction of the endoplasmic reticulum (ER). Although caspase-12 has been implicated in ER stress-induced apoptosis and amyloid-beta (Abeta)-induced apoptosis in rodents, it is controversial whether similar mechanisms operate in humans. We found that human caspase-4, a member of caspase-1 subfamily that includes caspase-12, is localized to the ER membrane, and is cleaved when cells are treated with ER stress-inducing reagents, but not with other apoptotic reagents. Cleavage of caspase-4 is not affected by overexpression of Bcl-2, which prevents signal transduction on the mitochondria, suggesting that caspase-4 is primarily activated in ER stress-induced apoptosis. Furthermore, a reduction of caspase-4 expression by small interfering RNA decreases ER stress-induced apoptosis in some cell lines, but not other ER stress-independent apoptosis. Caspase-4 is also cleaved by administration of Abeta, and Abeta-induced apoptosis is reduced by small interfering RNAs to caspase-4. Thus, caspase-4 can function as an ER stress-specific caspase in humans, and may be involved in pathogenesis of Alzheimer's disease.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007425 Intracellular Membranes Thin structures that encapsulate subcellular structures or ORGANELLES in EUKARYOTIC CELLS. They include a variety of membranes associated with the CELL NUCLEUS; the MITOCHONDRIA; the GOLGI APPARATUS; the ENDOPLASMIC RETICULUM; LYSOSOMES; PLASTIDS; and VACUOLES. Membranes, Intracellular,Intracellular Membrane,Membrane, Intracellular
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D009410 Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways. Neuron Degeneration,Degeneration, Nerve,Degeneration, Neuron,Degenerations, Nerve,Degenerations, Neuron,Nerve Degenerations,Neuron Degenerations
D004721 Endoplasmic Reticulum A system of cisternae in the CYTOPLASM of many cells. In places the endoplasmic reticulum is continuous with the plasma membrane (CELL MEMBRANE) or outer membrane of the nuclear envelope. If the outer surfaces of the endoplasmic reticulum membranes are coated with ribosomes, the endoplasmic reticulum is said to be rough-surfaced (ENDOPLASMIC RETICULUM, ROUGH); otherwise it is said to be smooth-surfaced (ENDOPLASMIC RETICULUM, SMOOTH). (King & Stansfield, A Dictionary of Genetics, 4th ed) Ergastoplasm,Reticulum, Endoplasmic
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D016229 Amyloid beta-Peptides Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue. Alzheimer beta-Protein,Amyloid Protein A4,Amyloid beta-Peptide,Amyloid beta-Protein,beta Amyloid,beta-Amyloid Protein,Alzheimer's ABP,Alzheimer's Amyloid Fibril Protein,Amyloid AD-AP,Amyloid Fibril Protein, Alzheimer's,Amyloid beta-Proteins,ABP, Alzheimer's,AD-AP, Amyloid,Alzheimer ABP,Alzheimer beta Protein,Alzheimers ABP,Amyloid AD AP,Amyloid beta Peptide,Amyloid beta Peptides,Amyloid beta Protein,Amyloid beta Proteins,Amyloid, beta,Protein A4, Amyloid,Protein, beta-Amyloid,beta Amyloid Protein,beta-Peptide, Amyloid,beta-Peptides, Amyloid,beta-Protein, Alzheimer,beta-Protein, Amyloid,beta-Proteins, Amyloid

Related Publications

Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
November 2011, Journal of neuroscience research,
Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
August 2005, The Journal of biological chemistry,
Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
June 2006, Human molecular genetics,
Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
January 2011, Journal of pharmacological sciences,
Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
January 2011, Journal of pharmacological sciences,
Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
July 2006, Experimental cell research,
Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
May 2013, Recent patents on anti-cancer drug discovery,
Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
June 2013, The Journal of biological chemistry,
Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
July 2005, Journal of the American Society of Nephrology : JASN,
Junichi Hitomi, and Taiichi Katayama, and Yutaka Eguchi, and Takashi Kudo, and Manabu Taniguchi, and Yoshihisa Koyama, and Takayuki Manabe, and Satoru Yamagishi, and Yoshio Bando, and Kazunori Imaizumi, and Yoshihide Tsujimoto, and Masaya Tohyama
February 2018, Scientific reports,
Copied contents to your clipboard!